Bionomics Limited (BNOEF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BNOEF steht fuer Bionomics Limited, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 56/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 18. März 2026Bionomics Limited (BNOEF) Gesundheitswesen & Pipeline-Uebersicht
Bionomics Limited, an Australian clinical-stage biopharmaceutical company, specializes in developing novel treatments for central nervous system disorders and cancers, with a focus on its lead drug candidate BNC210 targeting social anxiety and PTSD, positioning it within the competitive biotechnology landscape.
Investmentthese
Bionomics Limited presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful clinical development and potential commercialization of BNC210 for social anxiety disorder and post-traumatic stress disorder. Positive Phase 2 and Phase 2b trial results could serve as significant catalysts, potentially leading to partnerships or acquisition. However, the company's negative profit margin of -4546.6% and reliance on future clinical trial success present substantial risks. The company's market capitalization is $0.01 billion as of March 18, 2026. Investors should carefully weigh the potential upside against the inherent uncertainties of drug development and regulatory approval.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $0.01 billion, reflecting its small-cap status within the biotechnology sector.
- Negative P/E ratio of -0.06, indicative of current losses and the company's investment in research and development.
- Gross margin of 94.7%, suggesting strong potential profitability if drug candidates reach commercialization.
- Profit margin of -4546.6%, highlighting the significant expenses associated with clinical trials and drug development.
- Beta of 1.84, indicating higher volatility compared to the overall market, typical for biotechnology companies.
Wettbewerber & Vergleichsunternehmen
Staerken
- Novel drug candidates targeting unmet medical needs.
- Clinical-stage pipeline with multiple ongoing trials.
- Experienced management team with expertise in drug development.
- Strong intellectual property portfolio.
Schwaechen
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failure.
- Dependence on successful commercialization of a limited number of drug candidates.
- OTC market listing.
Katalysatoren
- Upcoming: Release of Phase 2 clinical trial results for BNC210 in social anxiety disorder.
- Upcoming: Initiation of Phase 3 clinical trials for BNC210, contingent on Phase 2 success.
- Ongoing: Enrollment and progress in Phase 2b clinical trials for BNC210 in post-traumatic stress disorder.
- Ongoing: Development and advancement of BNC101 and BNC105 through clinical trials.
- Potential: Announcement of partnerships or licensing agreements with larger pharmaceutical companies.
Risiken
- Potential: Failure to obtain regulatory approval for its drug candidates.
- Potential: Competition from other companies developing treatments for similar indications.
- Ongoing: Dependence on external funding to support clinical trials and operations.
- Ongoing: High cash burn rate and potential need for additional financing.
- Potential: Product liability claims and other legal challenges.
Wachstumschancen
- BNC210 for Social Anxiety Disorder (SAD): The market for SAD treatments is substantial, with millions affected globally. Successful Phase 2 trial results and subsequent commercialization of BNC210 could generate significant revenue for Bionomics. The timeline for potential market entry depends on clinical trial outcomes and regulatory approvals, but could be within the next 3-5 years. Bionomics' competitive advantage lies in the novel mechanism of action of BNC210.
- BNC210 for Post-Traumatic Stress Disorder (PTSD): PTSD represents another significant market opportunity, with a growing awareness of the condition and increasing demand for effective treatments. Positive Phase 2b trial results for BNC210 in PTSD could lead to accelerated development and commercialization. The timeline is similar to SAD, contingent on clinical trial success and regulatory pathways. Bionomics aims to address the limitations of existing PTSD treatments with BNC210.
- BNC101 for Cancer Stem Cells: Targeting cancer stem cells represents a novel approach to cancer treatment, with the potential to improve outcomes and reduce recurrence rates. Bionomics' BNC101, a monoclonal antibody, has completed Phase 1 clinical trials. Further development and clinical validation could open up significant opportunities in the oncology market. The timeline for commercialization is longer, potentially 5-7 years, due to the early stage of development.
- BNC105 for Refractory Colorectal Cancer: Colorectal cancer remains a leading cause of cancer-related deaths, and refractory cases present a significant challenge. Bionomics' BNC105 is in Phase 2 clinical trials for this indication. Positive results could lead to regulatory approval and market access. The timeline for potential commercialization is approximately 3-5 years, depending on clinical trial outcomes and regulatory review.
- Partnerships and Licensing Agreements: Bionomics can leverage its drug candidates and technology platform to establish partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide funding for further development and commercialization, while also expanding the reach of Bionomics' products. The timing and value of such agreements are uncertain, but they represent a significant growth opportunity for the company.
Chancen
- Successful clinical trial results leading to regulatory approval.
- Partnerships and licensing agreements with larger pharmaceutical companies.
- Expansion of pipeline through internal discovery and external acquisitions.
- Growing market demand for effective treatments for CNS disorders and cancers.
Risiken
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory hurdles and delays in drug approval processes.
- Unfavorable changes in healthcare policies and reimbursement rates.
- Product liability claims and other legal challenges.
Wettbewerbsvorteile
- Proprietary drug candidates with novel mechanisms of action.
- Intellectual property protection through patents and other forms of exclusivity.
- Clinical data supporting the safety and efficacy of its drug candidates.
Ueber BNOEF
Bionomics Limited, founded in 1996 and based in Eastwood, Australia, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative drug candidates. The company focuses on addressing unmet needs in the treatment of central nervous system (CNS) disorders and cancers. Bionomics' lead drug candidate, BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, is currently undergoing Phase 2 clinical trials for social anxiety disorder (SAD) and Phase 2b trials for post-traumatic stress disorder (PTSD). This drug represents a core element of their pipeline, targeting significant mental health conditions. In addition to BNC210, Bionomics is developing BNC101, a monoclonal antibody targeting cancer stem cells, which has completed Phase 1 clinical trials. The company also has BNC105, in Phase 2 clinical trials for refractory colorectal cancer and Phase 1 for relapsed/refractory chronic lymphocytic leukemia. Bionomics operates primarily in the biotechnology sector, focusing on drug discovery and clinical development. The company aims to create value through the successful development and commercialization of its drug candidates, addressing critical needs in both CNS disorders and oncology.
Was das Unternehmen tut
- Discovers novel drug candidates for central nervous system disorders and cancers.
- Develops BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor.
- Conducts Phase 2 clinical trials for BNC210 in social anxiety disorder.
- Conducts Phase 2b clinical trials for BNC210 in post-traumatic stress disorder.
- Develops BNC101, a monoclonal antibody targeting cancer stem cells.
- Conducts Phase 1 clinical trials for BNC101.
- Develops BNC105 for the treatment of refractory colorectal cancer and relapsed/refractory chronic lymphocytic leukemia.
Geschaeftsmodell
- Focuses on research and development of novel drug candidates.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered programs.
Branchenkontext
Bionomics Limited operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful drug candidates. The company focuses on CNS disorders and oncology, areas with substantial unmet needs and growing market demand. The biotechnology industry is driven by innovation and technological advancements, with companies constantly seeking to develop novel therapies and improve patient outcomes. Bionomics faces competition from larger pharmaceutical companies and other biotechnology firms developing treatments for similar indications.
Wichtige Kunden
- Pharmaceutical companies seeking to in-license or acquire novel drug candidates.
- Patients suffering from central nervous system disorders and cancers.
- Healthcare providers prescribing medications to treat these conditions.
Finanzdaten
Chart & Info
Bionomics Limited (BNOEF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Highs On Tuesday
· 24. März 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer BNOEF.
Kursziele
Wall-Street-Kurszielanalyse fuer BNOEF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von BNOEF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Spyridon Papapetropoulos
CEO
Spyridon Papapetropoulos is the Chief Executive Officer of Bionomics Limited. His background likely includes extensive experience in the pharmaceutical or biotechnology industry, with a focus on drug development, clinical trials, and regulatory affairs. He likely holds advanced degrees in science or business, such as a PhD or MBA. Prior to joining Bionomics, he may have held leadership positions at other pharmaceutical or biotechnology companies, overseeing research and development programs.
Erfolgsbilanz: Spyridon Papapetropoulos' track record at Bionomics Limited would be evaluated based on the company's progress in advancing its drug pipeline, securing partnerships, and achieving clinical milestones. Key achievements may include the successful completion of Phase 2 clinical trials for BNC210, the initiation of Phase 2b trials for PTSD, and the expansion of the company's intellectual property portfolio. Strategic decisions under his leadership would focus on prioritizing drug development programs and securing funding to support clinical trials.
BNOEF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bionomics Limited may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited trading volume and liquidity, and investors should exercise caution due to the increased risk of fraud or manipulation compared to companies listed on major exchanges like the NYSE or NASDAQ. OTC Other stocks often have less stringent listing requirements, leading to a higher concentration of speculative or distressed companies.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity and potential price volatility due to low trading volume.
- Higher risk of fraud or manipulation compared to companies listed on major exchanges.
- Less stringent disclosure requirements, potentially leading to incomplete or unreliable information.
- Potential for delisting or trading suspension due to non-compliance with OTC market regulations.
- Increased difficulty in obtaining accurate and timely financial information.
- Verify the company's registration and compliance with OTC market regulations.
- Review the company's financial statements and assess its financial health.
- Research the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Assess the potential risks and challenges facing the company.
- Consult with a qualified financial advisor before investing.
- Understand the limitations of information available for OTC-listed companies.
- Established history of operations since 1996.
- Focus on clinical-stage drug development with ongoing clinical trials.
- Intellectual property protection through patents and other forms of exclusivity.
- Presence of an experienced management team.
- Scientific publications or presentations supporting the company's drug candidates.
BNOEF Healthcare Aktien-FAQ
What are the key factors to evaluate for BNOEF?
Bionomics Limited (BNOEF) currently holds an AI score of 56/100, indicating moderate score. Key strength: Novel drug candidates targeting unmet medical needs.. Primary risk to monitor: Potential: Failure to obtain regulatory approval for its drug candidates.. This is not financial advice.
How frequently does BNOEF data refresh on this page?
BNOEF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BNOEF's recent stock price performance?
Recent price movement in Bionomics Limited (BNOEF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidates targeting unmet medical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BNOEF overvalued or undervalued right now?
Determining whether Bionomics Limited (BNOEF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BNOEF?
Before investing in Bionomics Limited (BNOEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BNOEF to a portfolio?
Potential reasons to consider Bionomics Limited (BNOEF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Novel drug candidates targeting unmet medical needs.. Additionally: Clinical-stage pipeline with multiple ongoing trials.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of BNOEF?
Yes, most major brokerages offer fractional shares of Bionomics Limited (BNOEF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BNOEF's earnings and financial reports?
Bionomics Limited (BNOEF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for BNOEF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data for exchange-listed companies.
- Clinical trial outcomes are inherently uncertain.